

February 24, 2015



# **Cryoport Provides Logistics Solution and Services for Kite Pharma's Lead Clinical Program in Cancer Immunotherapy**

LAKE FOREST, Calif., Feb. 24, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company's best-in-class logistics solution is supporting Kite Pharma's ("Kite") clinical program for their lead product candidate, KTE-C19, a CAR-T cell therapy for non-Hodgkin's lymphoma ("NHL").

Kite is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors.

David Chang, M.D., Ph.D., Kite's Executive Vice President of Research and Development and Chief Medical Officer, commented, "Cryoport has provided valuable cryogenic logistics solutions for our lead clinical program. We are grateful for their professionalism and their support in a role that is contributing greatly to our progress."

Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are honored to provide services and solutions to Kite in their efforts to advance a novel immunotherapy treatment that addresses the significant, unmet needs of patients with NHL. We are delighted that Cryoport's validated cryogenic logistics solutions will support Kite in moving closer to eradicating this deadly disease."

## **About Cryoport, Inc.**

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150 degrees C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoport™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit [www.cryoport.com](http://www.cryoport.com).

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your [iPhone and iPad](#) or [Android mobile device](#).

## **Forward Looking Statements**

*Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.*

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/cryoport-provides-logistics-solution-and-services-for-kite-pharmas-lead-clinical-program-in-cancer-immunotherapy-300040309.html>

SOURCE Cryoport, Inc.